General


Peptide: hepcidin 20
Microorganism:Staphylococcus epidermidis
Administration:
Stage: Formation (3-24h)
Notes:

Experimental procedure


Method AMP Effect(Biofilm reduction) Concentration Notes
Crystal violet assay 21 - 50% 3.12 uM Clinical isolate SeALE, PIA positive
Crystal violet assay 51 - 90% 6.25 uM Clinical isolate SeALE, PIA positive
Crystal violet assay 51 - 90% 3.12 uM Clinical isolate Se30, PIA positive
Crystal violet assay > 90% 12.5 uM Clinical isolate Se30, PIA positive
Crystal violet assay <= 20 % 3.12 uM Clinical isolate SeNOC, PIA positive
Crystal violet assay 21 - 50% 6.25 uM Clinical isolate SeNOC, PIA positive
Crystal violet assay 51 - 90% 25 uM Clinical isolate SeNOC, PIA positive
Crystal violet assay 21 - 50% 3.12 uM Clinical isolate SEVIC, PIA negative
Crystal violet assay 51 - 90% 12.5 uM Clinical isolate SEVIC, PIA negative
Crystal violet assay > 90% 50 uM Clinical isolate SEVIC, PIA negative
Crystal violet assay 21 - 50% 6.25 uM Clinical isolate SeNEG, PIA negative
Crystal violet assay 51 - 90% 12.5 uM Clinical isolate SeNEG, PIA negative
Crystal violet assay <= 20 % 6.25 uM Clinical isolate SeBER, PIA negative
Crystal violet assay 21 - 50% 12.5 uM Clinical isolate SeNEG, PIA negative
Crystal violet assay 51 - 90% 25 uM Clinical isolate SeNEG, PIA negative
Total countable CFUs Not Active 50 uM Clinical isolate SeNEG, PIA negative; 18 h incubation

Reference



M. Di Luca, G. Maccari, G. Maisetta, G. Batoni BaAMPs: the database of biofilm-active antimicrobial peptides Biofouling 2015; 31(2):193-9.

Please do not hesitate to address comments or questions to: mariagrazia.diluca@nano.cnr.it or gpmaccari@gmail.com